Emerade recall

Delivery issues halt production

Pharmaswiss Česka republika is initiating an urgent recall of all batches of Emerade 500 micrograms and Emerade 300 micrograms adrenaline auto-injectors.

This is due to an identified fault, where some auto-injectors fail to deliver the product or activate prematurely.

Due to the fault, future production of Emerade 500 micrograms and Emerade 300 micrograms auto-injectors is on hold, and patients will need to be switched to an appropriate alternative.

Evidence suggests that a single EpiPen (300 micrograms) or Jext (300 micrograms) pen are suitable replacements.

Healthcare professionals should ask patients, or carers of patients, who carry Emerade 300 or 500 microgram auto-injector pens to return their devices and obtain an alternative.

Patients and carers should also receive training to ensure they are completely familiar with how their new device works. Patients should continue to carry two devices at all times Further information is available in the recent Public Assessment Report: Recommendations to support the effective and safe use of adrenaline auto-injectors.

By 12 May 2023:

GP teams are asked to quarantine all remaining stock and return it to your supplier/MAH using your supplier’s approved process.
Identify affected patients to request a new prescription and return existing devices.

A template patient letter is available. Download Advice for patients who have been prescribed Emerade auto-injectors

MHRA alert